Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Cited by (1,000)

Items 101–200 of 1,000

1. FRAME Study: The Foundation Effect of Building Bone with 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
   Cosman, Felicia, Crittenden, Daria B, Ferrari, Serge, Khan, Aliya, Lane, Nancy E, Lippuner, Kurt, Matsumoto, Toshio, Milmont, Cassandra E, Libanati, Cesar, Grauer, Andreas · 2018 · Journal of Bone and Mineral Research
2. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study
   Henrik Toft Sørensen, Steffen Christensen, Frank Mehnert, Lars Henning Pedersen, Roland D Chapurlat, Steven Ron Cummings, John A. Baron · 2008 · BMJ
3. Epidemiology of fragility fractures and fall prevention in the elderly: a systematic review of the literature
   Takayuki Tsuda · 2017 · Current Orthopaedic Practice
4. Aging of mesenchymal stem cell: machinery, markers, and strategies of fighting
   Mahmoud Al‐Azab, Mohammed Safi, Elina Idiiatullina, Fadhl Al‐Shaebi, Mohamed Y. Zaky · 2022 · Cellular & Molecular Biology Letters
5. A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2
   Simon C. Mears, Stephen L. Kates · 2015 · Geriatric Orthopaedic Surgery & Rehabilitation
6. Oral bisphosphonates are associated with reduced mortality after hip fracture
   Lauren A Beaupré, Donald W. Morrish, David A. Hanley, Walter P. Maksymowych, Neil R. Bell, Angela G. Juby, Sumit R. Majumdar · 2010 · Osteoporosis International
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
   Sarah Davis, Emma L. Simpson, Jean Hamilton, Marrissa Martyn‐St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil J. L. Gittoes, Peter L. Selby · 2020 · Health Technology Assessment
8. Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
   John Paul Bilezikian · 2009 · The American Journal of Medicine
9. Incidence and demography of femur fractures with and without atypical features
   Adrianne C. Feldstein, Dennis M. Black, Nancy Perrin, A. Gabriela Rosales, Darin Friess, David Boardman, Richard M. Dell, Arthur C. Santora, Julie M Chandler, Mary M. Rix et al. · 2012 · Journal of Bone and Mineral Research
10. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
    Athanasios D. Anastasilakis, Socrates E. Papapoulos, Stergios A. Pοlyzos, Natasha M. Appelman‐Dijkstra, Polyzois Makras · 2019 · Journal of Bone and Mineral Research
11. High-dose oral vitamin D3 supplementation in the elderly
    Catherine J. Bacon, Greg D. Gamble, Anne M. Horne, Marilyn Scott, Ian R. Reid · 2008 · Osteoporosis International
12. Bisphosphonate-related osteonecrosis of the jaws – A review
    Sebastian Kühl, Christian Walter, Stephan Acham, Roland Pfeffer, J. Thomas Lambrecht · 2012 · Oral Oncology
13. Hip fracture: diagnosis, treatment, and secondary prevention.
    Kim LeBlanc, Herbert L. Muncie, Leanne L. LeBlanc · 2014 · PubMed
14. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment
    William Donald Leslie, Lisa Marie Lix, Lisa Langsetmo, Claudie Berger, David Goltzman, David A. Hanley, Jonathan Derrick Adachi, H. Johansson, Anders Odén, Eugene Vincent McCloskey et al. · 2010 · Osteoporosis International
15. Depression as a risk factor for osteoporosis
    Giovanni Cizza, Svetlana Primma, György Csákó · 2009 · Trends in Endocrinology and Metabolism
16. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml
    Amanda Carmel, Albert Shieh, Heejung Bang, Richard S. Bockman · 2012 · Osteoporosis International
17. Insights and implications of sexual dimorphism in osteoporosis
    Yuanyuan Zhang, Na Xie, Xiaodong Sun, Edouard Collins Nice, Yih‐Cherng Liou, Canhua Huang, Huili Zhu, Zhisen Shen · 2024 · Bone Research
18. 2018 update of French recommendations on the management of postmenopausal osteoporosis
    Karine Briot, Christian Roux, Thierry Thomas, Hubert Blain, Daniel Buchon, Roland D Chapurlat, Françoise Debiais, J.-M. Féron, Jean Bernard Gauvain, Pascal Guggenbuhl et al. · 2018 · Joint Bone Spine
19. Potential mediators of the mortality reduction with zoledronic acid after hip fracture
    Cathleen S Colon-Emeric, Peter G Mesenbrink, Kenneth W. Lyles, Carl F. Pieper, Steven Boonen, Pierre Dominique Delmas, Erik Fink Eriksen, Jay S Magaziner · 2009 · Journal of Bone and Mineral Research
20. Understanding the Mechanisms of Senile Osteoporosis: New Facts for a Major Geriatric Syndrome
    Gustavo Duque, Bruce Robert Troen · 2008 · Journal of the American Geriatrics Society
21. Adverse Effects of Bisphosphonates
    Bo Abrahamsen · 2010 · Calcified Tissue International
22. The kidney and bisphosphonates
    Paul D. Miller · 2011 · Bone
23. Bone Health and Osteoporosis Prevention and Treatment
    MARCUS MUÑOZ, KATHLEEN ROBINSON, Amal A Shibli-Rahhal · 2020 · Clinical Obstetrics & Gynecology
24. Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture
    Lee A. Jennings, Andrew David Auerbach, Judith H. Maselli, Penelope S. Pekow, Peter K. Lindenauer, Sei J. Lee · 2010 · Journal of the American Geriatrics Society
25. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures
    Willem Frederik Lems, Karsten Dreinhöfer, Heike Annette Bischoff-Ferrari, Michael Blauth, Edward J. Czerwinski, José António Pereira da Silva, Antonio Herrera, Pierre J Hoffmeyer, Tore Kristian Kvien, Ghassan Maalouf et al. · 2016 · Annals of the Rheumatic Diseases
26. Side effects of drugs for osteoporosis and metastatic bone disease
    Michael Kriegbaum Skjødt, Morten Frost, Bo Abrahamsen · 2018 · British Journal of Clinical Pharmacology
27. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
    Guido Kranenburg, Jonas W. Bartstra, Maaike Weijmans, Pim A. de Jong, Willem P.Th.M. Mali, Harald J J Verhaar, Frank L.J. Visseren, Wilko Spiering · 2016 · Atherosclerosis
28. Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs
    Willem Frederik Lems, Hennie G. Raterman · 2017 · Therapeutic Advances in Musculoskeletal Disease
29. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling
    Michelle Maree McDonald, Sukhdeep K. Dulai, Craig Godfrey, Negin Amanat, Tamara Sztynda, David Graham Little · 2008 · Bone
30. The American Orthopaedic Associationʼs “Own the Bone” Initiative to Prevent Secondary Fractures
    Laura Lowe Tosi, Richard E Gliklich, Krishna Kannan, Kenneth J. Koval · 2008 · Journal of Bone and Joint Surgery
31. Safety of bisphosphonates
    Michael Pazianas, Bo Abrahamsen · 2011 · Bone
32. Risks and Benefits of Bisphosphonate Therapies
    Carlen Reyes, Mette Friberg Hitz, Daniel Prieto‐Alhambra, Bo Abrahamsen · 2015 · Journal of Cellular Biochemistry
33. Maximising functional recovery following hip fracture in frail seniors
    Lauren A Beaupré, Ellen F. Binder, Ian Douglas Cameron, C Allyson Jones, Denise Orwig, Catherine Sherrington, Jay S Magaziner · 2013 · Best Practice & Research Clinical Rheumatology
34. Frailty, osteoporosis and hip fracture: Causes, consequences and therapeutic perspectives
    Yves Rolland, Gabor Abellán van Kan, Athanasios Benetos, Hubert Blain, Marc Bonnefoy, Philippe Chassagne, Claude Jeandel, Michel Laroche, Fati Nourhashémi, Philippe Orcel et al. · 2008 · The journal of nutrition health & aging
35. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Jacques P. Brown, Suzanne N. Morin, William Donald Leslie, Αλεξάνδρα Παπαϊωάννου, Angela M. Cheung, Kenneth Shawn Davison, David Goltzman, David A. Hanley, Anthony B. Hodsman, Robert Josse et al. · 2014 · Europe PMC (PubMed Central)
36. Effect of osteoporosis medications on fracture healing
    Vishal V. Hegde, J. E. Jo, Panagiota Andreopoulou, Joseph M. Lane · 2015 · Osteoporosis International
37. Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies
    Leon A. Assael · 2009 · Journal of Oral and Maxillofacial Surgery
38. Safety issues with bisphosphonate therapy for osteoporosis
    Ernest Suresh, Michael Pazianas, Bo Abrahamsen · 2013 · Rheumatology
39. The Risk of a Second Hip Fracture in Patients after Their First Hip Fracture
    Hiroshi Hagino, Takeshi Sawaguchi, Naoto Endo, Yasuyo Ito, Tetsuo Nakano, Yoshinobu Watanabe · 2011 · Calcified Tissue International
40. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012
    Diane K. Wysowski, Patty Greene · 2013 · Bone
41. Osteoporosis and mortality
    Ariane Leboime, Cyrille B. Confavreux, Nadia Mehsen, Julien Paccou, Claire David, Christian Roux · 2010 · Joint Bone Spine
42. The relevance of biomaterials to the prevention and treatment of osteoporosis
    Daniel Arcos, Aldo Roberto Boccaccini, Marc Bohner, Adolfo Díez‐Pérez, Matthias Epple, Enrique Gómez‐Barrena, Antonio Herrera, Josep Anton Planell, Leocadio Rodríguez‐Mañas, María Vallet‐Regí · 2014 · Acta Biomaterialia
43. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women
    Sammy Elmariah, Joseph A. Delaney, Kevin D. O’Brien, Matthew Jay Budoff, Jens Vogel‐Claussen, Valentı́n Fuster, Richard A. Kronmal, Jonathan L. Halperin · 2010 · Journal of the American College of Cardiology
44. Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
    Steven Boonen, Dennis M. Black, Cathleen S Colon-Emeric, Richard Eastell, Jay S Magaziner, Erik Fink Eriksen, Peter G Mesenbrink, Patrick Haentjens, Kenneth W. Lyles · 2010 · Journal of the American Geriatrics Society
45. Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
    Dae Hyun Kim, James R. Rogers, Lisa A. Fulchino, Caroline A. Kim, Daniel H. Solomon, Seoyoung C. Kim · 2015 · PLoS ONE
46. A review of drug-induced hypocalcemia
    George L. Liamis, Haralampos J. Milionis, Moses Elisaf · 2009 · Journal of Bone and Mineral Metabolism
47. A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement
    Hubert Blain, Tahir Masud, Patricia Dargent‐Molina, Finbarr C. Martin, Erik Rosendahl, Nathalie van der Velde, Jean J. Bousquet, Athanasios Benetos, Cyrus C. Cooper, John А. Kanis et al. · 2016 · The journal of nutrition health & aging
48. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
    Zhanna E. Belaya, K. Yu. Belova, Elena Valer'evna Biryukova, Ivan Ivanovich Dedov, Larisa Konstantinovna Dzeranova, Oksana M. Drapkina, Alexander Vasil'evich Dreval', Т. A. Dubovitskaya, Е. N. Dudinskaya, Olga B. Ershova et al. · 2021 · Osteoporosis and Bone Diseases
49. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture
    Erik Fink Eriksen, Kenneth W. Lyles, Cathleen S Colon-Emeric, Carl F. Pieper, Jay S Magaziner, Jonathan Derrick Adachi, Lars Hyldstrup, Chris P. Recknor, Lars Nordsletten, Catherine Lavecchia et al. · 2009 · Journal of Bone and Mineral Research
50. Risk factors for in-hospital post-hip fracture mortality
    Steven Alfred Frost, Nguyen D Nguyen, Deborah Ann Black, John A. Eisman, Tuan V. Nguyen · 2011 · Bone
51. Bisphosphonates for postmenopausal osteoporosis
    Richard Eastell, Jennifer Walsh, Nelson B. Watts, Ethel S. Siris · 2011 · Bone
52. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
    Celia Louise Gregson, David Armstrong, Christina Avgerinou, Jean Bowden, Cyrus C. Cooper, Lucy Douglas, John Edwards, Neil J. L. Gittoes, Nicholas C. Harvey, John A. Kanis et al. · 2025 · Archives of Osteoporosis
53. Osteoporosis in men
    Peter Robert Ebeling · 2013 · Current Opinion in Rheumatology
54. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study
    Philip N. Sambrook, Ian Douglas Cameron, Jian Sheng Chen, LYN M. MARCH, Judy M. Simpson, Robert Graham Cumming, Markus J. Seibel · 2010 · Osteoporosis International
55. Bisphosphonates: how do they work?
    Socrates E. Papapoulos · 2008 · Best Practice & Research Clinical Endocrinology & Metabolism
56. The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid
    John T. Grbic, Dennis M. Black, Kenneth W. Lyles, David M. Reid, ERIC S. ORWOLL, Michael R. McClung, Christina M. Bucci-Rechtweg, Guoqin Su · 2010 · The Journal of the American Dental Association
57. Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper
    Jörg Goldhahn, Jean-Marc Féron, John А. Kanis, Socrates E. Papapoulos, Jean‐Yves Reginster, René Rizzoli, Willard H. Dere, Bruce Mitlak, Yannis Tsouderos, Steven Boonen · 2012 · Calcified Tissue International
58. Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
    Silvano Adami, Cesar R. Libanati, Steven Boonen, Steven Ron Cummings, Pei‐Ran Ho, Andrea Wang, Ethel S. Siris, Joseph M. Lane · 2012 · Journal of Bone and Joint Surgery
59. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
    Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Polyzois Makras · 2018 · European Journal of Endocrinology
60. Bisphosphonates and Atrial Fibrillation
    Yoon Kong Loke, Vinodh Jeevanantham, Sonal Singh · 2009 · Drug Safety
61. A Guide to Improving the Care of Patients With Fragility Fractures
    Susan V. Bukata, Benedict F. DiGiovanni, Susan M. Friedman, Harry A. Hoyen, Amy Kates, Stephen L. Kates, Simon C. Mears, Daniel Ari Mendelson, Fernando H. Serna, Frederick E. Sieber et al. · 2011 · Geriatric Orthopaedic Surgery & Rehabilitation
62. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
    Steven Boonen, Deborah E. Sellmeyer, Kurt Lippuner, Alexander Orlov-Morozov, Kenneth B. Abrams, Peter G Mesenbrink, Erik Fink Eriksen, Paul D. Miller · 2008 · Kidney International
63. Pharmacological treatment of osteoporosis in the oldest old
    Anne-Marie Vandenbroucke, Frank P. Luyten, Johan Flamaing, Evelien Gielen · 2017 · Clinical Interventions in Aging
64. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis
    Galina Afanas'evna Mel'nichenko, Zhanna E. Belaya, Liudmila Y. Rozhinskaya, Natalia V. Toroptsova, Lyudmila Ivanovna Alekseeva, Elena Valer'evna Biryukova, Tatiana A. Grebennikova, Larisa Konstantinovna Dzeranova, Alexander Vasil'evich Dreval', N. V. Zagorodniy et al. · 2018 · Problems of Endocrinology
65. Age Related Osteoporosis: Targeting Cellular Senescence
    Ursula Föger‐Samwald, Katharina Kerschan‐Schindl, Maria Butylina, Peter Pietschmann · 2022 · International Journal of Molecular Sciences
66. Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
    Pierre Dominique Delmas, Françoise Munoz, Dennis M. Black, Felicia Cosman, Steven Boonen, Nelson B. Watts, David L. Kendler, Erik Fink Eriksen, Peter G Mesenbrink, Richard Eastell · 2009 · Journal of Bone and Mineral Research
67. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
    Joshua D. Hutcheson, Claudia Goettsch · 2023 · Circulation Research
68. Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?
    Tahir Masud, Neil Binkley, Steven Boonen, Marian T. Hannan · 2011 · Journal of Clinical Densitometry
69. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
    Bovijn, Jonas, Krebs, Kristi, Chen, Chia-Yen, Boxall, Ruth, Censin, Jenny C., Ferreira, Teresa, Pulit, Sara L., Glastonbury, Craig A., Laber, Samantha, Millwood, Iona Y. et al. · 2020 · Science Translational Medicine
70. Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study
    Seoyoung C. Kim, Mi‐Sook Kim, Gabriel Sanfélix‐Gimeno, Hong Ji Song, Jun Liu, Isabel Hurtado, Salvador Peiró, Joongyub Lee, Nam‐Kyong Choi, Byung‐Joo Park et al. · 2015 · The American Journal of Medicine
71. Mortality and osteoporotic fractures: is the link causal, and is it modifiable?
    Gim Gee Teng, Jeffrey R. Curtis, Kenneth G. Saag · 2008 · PubMed
72. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass
    Michael R. McClung, Paul D. Miller, Chris P. Recknor, Peter G Mesenbrink, Christina M. Bucci-Rechtweg, Claude-Laurent Benhamou · 2009 · Obstetrics and Gynecology
73. The Potential Economic Benefits of Improved Postfracture Care: A Cost-Effectiveness Analysis of a Fracture Liaison Service in the US Health-Care System
    Daniel H. Solomon, Amanda R. Patrick, John T. Schousboe, Elena Losina · 2014 · Journal of Bone and Mineral Research
74. Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
    Pierre Dominique Delmas · 2008 · Journal of Clinical Densitometry
75. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide
    Miyakoshi, Naohisa, Aizawa, Toshiaki, Sasaki, Satoshi, Ando, Shigeru, Maekawa, Shigeto, Aonuma, Hiroshi, Tsuchie, Hiroyuki, Sasaki, Hiroshi, Kasukawa, Yuji, Shimada, Yoichi · 2015 · Journal of Bone and Mineral Metabolism
76. Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial
    Andrew B. Grey, Mark J Bolland, Anne M. Horne, Diana J. Wattie, Meaghan E House, Greg D. Gamble, Ian R. Reid · 2012 · Bone
77. Atrial fibrillation in fracture patients treated with oral bisphosphonates
    Bo Abrahamsen, Pia Eiken, Kim Brixen · 2009 · Journal of Internal Medicine
78. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion
    Francesco Bertoldo, Serena Pancheri, Sonia Zenari, Stefania Boldini, B. Giovanazzi, Mirko Zanatta, Maria Teresa Valenti, Luca Dalle Carbonare, Vincenzo Lo Cascio · 2009 · Journal of Bone and Mineral Research
79. Renal safety in patients treated with bisphosphonates for osteoporosis: A review
    Paul D. Miller, Sophie A. Jamal, Pieter Evenepoel, Richard Eastell, Steven Boonen · 2013 · Journal of Bone and Mineral Research
80. The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
    Andrew B. Grey, Mark J Bolland, Diana J. Wattie, Anne M. Horne, Greg D. Gamble, Ian R. Reid · 2008 · The Journal of Clinical Endocrinology & Metabolism
81. Association between timing of zoledronic acid infusion and hip fracture healing
    for the HORIZON Recurrent Fracture Trial, Cathleen S Colon-Emeric, Lars Nordsletten, Samantha N. Olson, Nancy M. Major, Steven Boonen, Patrick Haentjens, Peter G Mesenbrink, Jay S Magaziner, Jonathan Derrick Adachi et al. · 2010 · Osteoporosis International
82. Overdiagnosis of bone fragility in the quest to prevent hip fracture
    Teppo L. N. Järvinen, Karl Michaëlsson, Jarkko Jokihaara, Professor Gary S. Collins, Thomas L. Perry, Barbara J. Mintzes, Vijaya Manav Musini, Juan Erviti, Javier Gorricho, Jeffrey M. Wright et al. · 2015 · BMJ
83. Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture
    Kirsten M. B. Huntjens, S. Kosar, Tineke A. C. M. van Geel, Piet Geusens, Paul C. P. H. Willems, Alfons G.H. Kessels, Björn Winkens, Peter R.G. Brink, Sven H. van Helden · 2010 · Osteoporosis International
84. The clinical role of dual energy X-ray absorptiometry
    Glen Mervyn Blake, Ignac Fogelman · 2009 · European Journal of Radiology
85. Long-term functional outcome in geriatric hip fracture patients
    Christian Kammerlander, Markus Gosch, Ursula Kammerlander-Knauer, Thomas J. Luger, Michael Blauth, Tobias Roth · 2011 · Archives of Orthopaedic and Trauma Surgery
86. Treatment of osteoporosis in men
    JM Kaufman, J.-Y. Reginster, Steven Boonen, Maria Luisa Brandi, Cyrus C. Cooper, Willard H. Dere, J.-P. Devogelaer, Adolfo Díez‐Pérez, John А. Kanis, Eugene Vincent McCloskey et al. · 2012 · Bone
87. Bisphosphonates for the treatment of osteoporosis: insights for clinicians
    Edward Michael Lewiecki · 2010 · Therapeutic Advances in Chronic Disease
88. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
    Taichi Saito, Jennifer M. Sterbenz, Sunitha Malay, L. Zhong, Mark MacEachern, Kevin C. Chung · 2017 · Osteoporosis International
89. Skeletal Aging
    Jad G. Sfeir, Matthew T. Drake, Sundeep Khosla, Joshua N. Farr · 2022 · Mayo Clinic Proceedings
90. Clinical Practice Guideline for Postoperative Rehabilitation in Older Patients With Hip Fractures
    Kyunghoon Min, Jaewon Beom, Bo Ryun Kim, Sang Yoon Lee, Goo Joo Lee, Jung Hwan Lee, Seung Yeol Lee, Sun Jae Won, Sangwoo Ahn, Heui Je Bang et al. · 2021 · Annals of Rehabilitation Medicine
91. Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture
    Seoyoung C. Kim, Dae Hyun Kim, Helen Mogun, Wesley Eddings, Jennifer M. Polinski, Jessica Myers Franklin, Daniel H. Solomon · 2016 · Journal of Bone and Mineral Research
92. Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men
    Shabbir M.H. Alibhai, Minh Duong-Hua, Angela M. Cheung, Rinku Sutradhar, Padraig Richard Warde, Neil Eric Fleshner, Lawrence Frank Paszat · 2010 · The Journal of Urology
93. Fracture healing in the elderly: A review
    Bradley A. Foulke, Adrian R. Kendal, David W. Murray, Hemant G. Pandit · 2016 · Maturitas
94. Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
    Ian R. Reid, Dennis M. Black, Richard Eastell, Christina M. Bucci-Rechtweg, G. Su, Trisha F. Hue, Peter G Mesenbrink, Kenneth W. Lyles, Steven Boonen · 2013 · The Journal of Clinical Endocrinology & Metabolism
95. Excess mortality attributable to hip-fracture: A relative survival analysis
    Steven Alfred Frost, Nguyen D Nguyen, John A. Eisman, Tuan V. Nguyen · 2013 · Bone
96. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
    J.J. Body, P. Bergmann, Steven Boonen, Y. Boutsen, J.-P. Devogelaer, Stefan Goemaere, Jean‐Marc Kaufman, Serge Rozenberg, J.-Y. Reginster · 2010 · Osteoporosis International
97. Postmenopausal osteoporosis: Assessment and management
    René Rizzoli · 2018 · Best Practice & Research Clinical Endocrinology & Metabolism
98. Hormones and Aging: An Endocrine Society Scientific Statement
    Anne Rentoumis Cappola, Richard Joseph Auchus, Ghada El‐Hajj Fuleihan, David J. Handelsman, Rita Rastogi Kalyani, Michael R. McClung, Cynthia A. Stuenkel, Michael O. Thorner, Joseph George Verbalis · 2023 · The Journal of Clinical Endocrinology & Metabolism
99. Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study
    Inger Hallberg, Margareta Bachrach‐Lindström, Staffan Hammerby, Göran Toss, Anna‐Christina Ek · 2009 · BMC Musculoskeletal Disorders
100. Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis
     Edward Michael Lewiecki · 2011 · Drugs